Core Insights - The article discusses the performance and potential of micro-cap stocks, particularly highlighting the impressive gains of the Russell Microcap index, which surged 74.5% from April 8, 2025, to February 28, 2026, outperforming larger indices like the Russell 1000 and S&P 500, which gained 39.7% and 39.6% respectively [2][3]. Micro-Cap Performance - Micro-caps have shown sustained market leadership due to better relative earnings growth driven by a strong US economy [3]. - The performance of micro and small-caps is also attributed to tougher comparisons for major tech stocks (Mag 7) due to inflated earnings expectations related to AI capital expenditure [3]. Investment Methodology - The article outlines a methodology for selecting penny stocks (priced under $5) that are trading within 0% to 10% of their 52-week highs, focusing on companies with recent noteworthy developments likely to impact investor sentiment [6]. - The selection process emphasizes stocks that are popular among analysts and elite hedge funds, as imitating top hedge fund picks has historically led to market outperformance [7]. Featured Penny Stocks - **Acacia Research Corporation (NASDAQ:ACTG)**: - The company has a price target raised from $5 to $6 by Craig-Hallum, indicating potential undervaluation despite mixed market conditions [8][9]. - Acacia reported a 2.63% year-over-year revenue growth to $50.13 million for fiscal Q4 2025, exceeding expectations by $12.13 million, with an EPS of $0.03 surpassing consensus by $0.17 [10]. - The company is involved in industrial, energy, and technology sectors, with a focus on intellectual property assets [11]. - **Ocugen, Inc. (NASDAQ:OCGN)**: - Initiated with an Outperform rating and a $10 price target, Ocugen is positioned as a leader in gene therapy for blinding ocular disorders, with its lead asset OCU400 in Phase 3 trials for retinitis pigmentosa [12][13]. - The company is developing multiple programs for retinal diseases and expects to file three FDA applications over the next three years [14].

Group 1 - The AI capital expenditure boom is projected to exceed $400 billion in borrowing this year, significantly higher than the $165 billion raised in 2025 [1] - Concerns are raised regarding the opacity of AI debt exposure, as funding methods like special purpose vehicles and off-balance-sheet financing may not be immediately visible to investors [2] - A Bank of America survey indicates a decline in fund managers advocating for increased capital spending, with only 20% supporting it, down from 34% the previous month [3] Group 2 - Prediction markets suggest a 20% probability of an industry downturn by the end of 2026, with specific triggers identified such as a 50% drop in Nvidia's stock price [4] - The net notional CDS outstanding for major tech companies has surged to nearly $10 billion, indicating a rush among investors to hedge against AI debt exposure [5]

Group 1 - Nobel Prize-winning economist Paul Krugman criticized President Trump's nomination of Kevin Warsh as Fed Chair, calling it "a big humiliation for the Fed" [1] - Krugman warned that the biggest risk to the dollar is not a rival currency but the potential for it to be replaced by "nothing," leading to a chaotic international monetary system [2] - He expressed skepticism about Warsh's record, stating he is a "hawk" only when a Democrat is in the White House and described the selection process for Fed Chair as degraded [3] Group 2 - Krugman noted that tariffs have raised prices by about 1% compared to what they would have been without them, ahead of a Supreme Court hearing on Trump's tariff authority [4] - He highlighted a $500-600 billion AI capital expenditure boom that is increasingly risky, with a shift from retained earnings to debt funding [5] - Goldman Sachs forecasts gold could reach $5,400 by year-end, driven by sustained central bank buying, while JP Morgan targets $6,300 with expectations of 800 tons of official-sector purchases in 2026 [5]